DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
Location: United States, Massachusetts, Medfield
Member count: 11-50
Total raised: $40M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 01.12.2020 | 5AM Ventur... | 5amventure... |
| - | Atlas Vent... | atlasventu... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 30.11.2020 | Series A | $40M | - | citybizlis... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 01.12.2020 | Kinaset Th... | Kinaset Therapeutics, a develo... | - | - | pitchbook.... |
| 30.11.2020 | Kinaset Th... | - | - | - | 5amventure... |
| 30.11.2020 | Kinaset Th... | MEDFIELD, Mass.--(BUSINESS WIR... | - | - | citybizlis... |
| 30.11.2020 | Kinaset Th... | MEDFIELD, MA, Kinaset Therap... | - | - | vcnewsdail... |